Wells Fargo Downgrades Teva Pharma (TEVA) to Market Perform
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $37.42 +1.66%
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
17 Buy, 22 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Wells Fargo downgraded Teva Pharma (NYSE: TEVA) from Outperform to Market Perform and lowered their valuation range from $45-$48 to $43-$45. The downgrade was a part of the firm's broader downgrade of the Drug sector rating to Market Weight from Overweight.
On the downgrade, the firm aid the the turnaround plan has evolved slower than they had thought, and potential approval of BG-12 could put further pressure on TEVA's P/E multiple.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $40.82 yesterday.
On the downgrade, the firm aid the the turnaround plan has evolved slower than they had thought, and potential approval of BG-12 could put further pressure on TEVA's P/E multiple.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $40.82 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Bill.com Holdings Inc. (BILL) PT Raised to $59 at TD Cowen
- Flux Power Holdings (FLUX) PT Lowered to $1.60 at Roth/MKM
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
